[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618106":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":13,"locations":19,"responsibleParty":100,"collaborators":102,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":10,"eligibilityCriteria":119,"healthyVolunteers":115,"sex":120,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":126,"studyType":127,"phases":10,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},{"fullName":5,"class":6},"Synermore Biologics (Suzhou) Co., Ltd.","INDUSTRY",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"SYN023 combined with rabies vaccine",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Other rabies passive immunization products combined with rabies vaccine",[14],{"name":15,"role":16,"phone":17,"phoneExt":10,"email":18},"Xiangjun Li","CONTACT","+86 0512-8765807","xjli@synermore.cn",[20,40,54,63,76,88],{"facility":21,"status":22,"city":23,"state":24,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Peking University First Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":28,"coordinates":29},"Point",[30,31],116.39723,39.9075,{"lat":31,"lon":30},[34,38],{"name":35,"role":16,"phone":36,"phoneExt":10,"email":37},"Si Liu","+86 13501220344","DocLeo@vip.sina.com",{"name":35,"role":39,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":41,"status":22,"city":42,"state":43,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"Shenzhen second people's hospital","Shenzhen","Guangdong",{"type":28,"coordinates":45},[46,47],114.0683,22.54554,{"lat":47,"lon":46},[50,53],{"name":51,"role":16,"phone":52,"phoneExt":10,"email":10},"Zhe Deng","+86 0755 83366388",{"name":51,"role":39,"phone":10,"phoneExt":10,"email":10},{"facility":55,"status":22,"city":42,"state":43,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"The University of Hong Kong - Shenzhen Hospital",{"type":28,"coordinates":57},[46,47],{"lat":47,"lon":46},[60,62],{"name":61,"role":16,"phone":10,"phoneExt":10,"email":10},"Haibing Xiao",{"name":61,"role":39,"phone":10,"phoneExt":10,"email":10},{"facility":64,"status":22,"city":65,"state":66,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Hunan Provincial People's Hospital","Changsha","Hunan",{"type":28,"coordinates":68},[69,70],112.97087,28.19874,{"lat":70,"lon":69},[73,75],{"name":74,"role":16,"phone":10,"phoneExt":10,"email":10},"Xiaotong Han",{"name":74,"role":39,"phone":10,"phoneExt":10,"email":10},{"facility":77,"status":22,"city":78,"state":66,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Affiliated Nanhua Hospital, University of South China","Hengyang",{"type":28,"coordinates":80},[81,82],112.61888,26.88946,{"lat":82,"lon":81},[85,87],{"name":86,"role":16,"phone":10,"phoneExt":10,"email":10},"Wenkai Bin",{"name":86,"role":39,"phone":10,"phoneExt":10,"email":10},{"facility":89,"status":22,"city":90,"state":91,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Jiangxi Provincial Chest Hospital","Nanchang","Jiangxi",{"type":28,"coordinates":93},[94,95],115.85306,28.68396,{"lat":95,"lon":94},[98],{"name":99,"role":39,"phone":10,"phoneExt":10,"email":10},"Qilong Zhang",{"type":101,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[103,105,107,108,110],{"name":21,"class":104},"OTHER",{"name":106,"class":104},"Shenzhen Second People's Hospital",{"name":64,"class":104},{"name":109,"class":104},"The University of Hong Kong-Shenzhen Hospital",{"name":111,"class":112},"University of South China Affiliated Nanhua Hospital","UNKNOWN","100618106","real-world-evidence-study-of-syn023-in-children-exposed-to-rabies-100618106",false,"NCT07327307","Real World Evidence Study of SYN023 in Children Exposed to Rabies","A Real-World Registry Study to Evaluate Clinical Protection Outcomes Following Post-Exposure Prophylaxis With Zamerovimab and Mazorelvimab Injection in Combination With Rabies Vaccine in Pediatric With Category III Rabies Exposure","Inclusion Criteria:\n\n1. Age under 18 years on the day of enrollment, regardless of gender, and able to provide legal proof of identity;\n2. Individuals with WHO Category III rabies exposure, and the time from exposure to the initiation of Post-Exposure Prophylaxis (PEP) is \\\u003C7 days;\n3. Have completed standardized wound management, injection of Zamerovimab and Mazorelvimab Injection \u002Fother passive immunization products, and the first dose of rabies vaccination within 24 hours prior to screening;\n4. The volunteer's guardian voluntarily agrees to their participation in the study and signs the informed consent form. Specifically: for volunteers under 8 years old, the guardian signs the informed consent form with the child's assent fully respected; for volunteers aged 8-17, the guardian signs the informed consent form, and the minor volunteer signs the minor assent form;\n5. Willing and able to comply with all study procedures, and is expected to be able to complete the full course of rabies vaccination and the 1-year follow-up as required (with no plans for long-term absence or relocation from the study area).\n\nExclusion Criteria:\n\n1. Based on inquiry, besides the current Category III rabies exposure, there is a history of bites by dogs, cats, mongooses, foxes, ferrets, skunks, bats, or raccoons within the past year;\n2. Other conditions considered by the investigator as unsuitable for participation in this study.","ALL","0 Years","17 Years",{"count":124,"type":125},232,"ESTIMATED","1 Year","OBSERVATIONAL","This observational study is an open-label, prospective, multi-center design. The goal is to evaluate the long-term clinical survival outcomes at 3 months and 1 year in individuals under 18 years of age with WHO Category III rabies exposure who have received real-world Post-Exposure Prophylaxis (PEP) with Zamerovimab and Mazorelvimab Injection \u002F other passive immunization products combined with the rabies vaccine.\n\nParticipants will: (1) Have their clinical protection outcomes (rabies-free survival status) registered and evaluated on Day 90 and Day 365. (2) Have the option to provide a blood sample on Day 7 for Rabies Virus Neutralizing Antibody (RVNA) testing. (3) Have all adverse events (within 42 days) and all serious adverse events (within 126 days) after PEP administration collected and recorded.",[130],"Rabies Post-exposure Prophylaxis",[132,133,134],"rabies","SYN023","pediatric","2026-04-21",{"date":137,"type":138},"2026-04-23","ACTUAL",{"date":140,"type":138},"2025-08-02",{"date":142,"type":125},"2026-12-31",{"name":5,"class":6},6]